Additionally, SARS-CoV-2 interacts with the immune system triggering dysfunctional immune responses to COVID-19 progression 1 . Given that an excessive inflammatory response to the novel coronavirus is thought to be a major cause of disease severity and death , a better understanding of the immunological underpinnings is required to identify potential therapeutic targets. To fill in this gap, we performed in silico analyses of immune system protein-protein interactome (PPi) network, single-cell RNA sequencing (scRNA-seq) of human tissues, and artificial neural networks to reveal potential therapeutic targets for drug repurposing against COVID-19.